Loss of asthma control after cessation of omalizumab treatment: Real life data

Postepy Dermatologii i Alergologii

Volumn 31, Issue 1, 2014, Pages 1-5

  Kupryś Lipińska, Izabela ^a   Kuna, Piotr ^a  

^a Department of Internal Medicine Asthma and Allergy Norbert Barlicki Memorial University Hospital No 1 Medical University of Lodz ^*  (Poland)

Author keywords

Asthma deterioration; Discontinuation; Exacerbations; Omalizumab; Severe asthma

Indexed keywords

CORTICOSTEROID; OMALIZUMAB; PREDNISONE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MALE; MIDDLE AGED; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84896777422     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2014.40553     Document Type: Article

References (20)

1. Kupryś I, Kuna P. Epidemics of allergic diseases: a new health problem in the modern world. Pol Merkur Lekarski 2003; 14: 453-5. (Pubitemid 36749682)
2. Kupryś-Lipińska I, Kuna P. Praktyczne wskazówki dotycza̧ce terapii omalizumabem [Polish]. Terapia 2011; 255: 42-8.
3. Marandi Y, Farahi N, Hashjin GS. Asthma: beyond corticosteroid treatment. Arch Med Sci 2013; 9: 521-6.
4. Mathew J, Aronow WS, Chandy D. Therapeutic options for severe asthma. Arch Med Sci 2012; 8: 589-97.
5. Kupryś-Lipińska I, Kuna P. Omalizumab, recombinant humanized monoclonal antibody anti-IgE; new fields of studies on the therapeutic indications. Pneumonol Alergol Pol 2009; 77: 43-51.
6. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-16. (Pubitemid 40293346)
7. Panek M, Pietras T, Kupryś-Lipińska I, et al.The analysis of the factors influencing the development of glucocorticoid resistance in the etiopathogenesis of severe bronchial asthma. Postepy Biochem 2010; 56: 373-82.
8. Kupczyk M, Haahtela T, Cruz AA, Kuna P. Reduction of asthma burden is possible through National Asthma Plans. Allergy 2010; 65: 415-9.
9. www.ginastha.org
10. Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis 2012; 6: 87-95.
11. Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008; 63: 670-84. (Pubitemid 351591863)
12. Oba Y, Salzman GA. Cost-efectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265-9. (Pubitemid 39119022)
13. Bodzenta-Łukaszczyk A, Chazan R, Fal A, et al. Statement of the Expert Group of Polish Society of Allergology on a therapeutic program of severe allergic asthma treatment with omalizumab. Alergologia Info 2010; 3: 106-7.
14. Corren J, Shapiro G, Reimann J, et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008; 121: 506-11. (Pubitemid 351215181)
15. Slavin RG, Ferioli C, Tannenbaum SJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123: 107-13.
16. Lowe P, Tannenbaum S, Gautier A, et al. Omalizumab (Xolair) may normalize IgE production rate in patients with moder-ate-to-severe atopic asthma. J Allergy Clin Immunol 2009; 123: S152.
17. Almeida E, Faria E, Ribeiro F, Luis A. Omalizumab in treatment-resistant severe asthma. When to stop? Allergy 2011; 66, Suppl.: 320-481
18. Molimard M, Le Gros V, Bourdeix I. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control ERS 2012 Abstract Book.
19. Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair: a 3-year withdrawal follow-up. Allergy 2010; 65: 56-60.
20. Bonifazi F, Jutel M, Biló BM, et al.; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60: 1459-70. (Pubitemid 41654315)